Inflammatix Stock

inflammatix.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $160.26MM

Inflammatix uses molecular diagnostics to read the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens.

Register for Details

For more details on financing and valuation for Inflammatix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Inflammatix.

Register Today

Other companies like Inflammatix in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Inflammatix Receives Additional $12.1M BARDA Funding for MDx Acute Infection Test, System
The award represents the third tranche of funding from a test development contract worth up to $72 million if all options are exercised.
Updated on: Sep 29, 2023